Department of Pathology, School of Medicine, University of Washington, Seattle, WA 98104, USA.
Int J Cancer. 2012 Nov 15;131(10):2300-7. doi: 10.1002/ijc.27520. Epub 2012 Mar 29.
Although the lineages of human papillomavirus type 31 (HPV31) variants are recognized, their clinical relevance is unknown. The purpose of our study was to examine risk of cervical intraepithelial neoplasia Grades 2-3 (CIN2/3) by HPV31 variants. Study subjects were women who participated in the atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion Triage Study and who had HPV31 infections detected at one or more visits. They were followed semi-annually over 2 years for detection of HPV DNA and cervical lesion. HPV31 isolates were characterized by DNA sequencing and assigned into 1 of 3 variant lineages. CIN2/3 was histologically confirmed in 127 (27.0%) of the 470 HPV31-positive women, 83 diagnosed at the first HPV31-positive visit and 44 thereafter. The odds ratio for the association of 2-year cumulative risk of CIN2/3 was 1.7 (95% CI: 1.0-2.9) for infections with A variants and 2.2 (95% CI: 1.2-3.9) for infections with B variants as compared to those with C variants. Among women without CIN2/3 at the first HPV31-positive visit, the risk of subsequent CIN2/3 was 2.2-fold greater for those with A variants (95% CI: 1.0-4.8) and 2.0-fold greater for those with B variants (95% CI: 0.9-4.9) as compared to those with C variants. Similar associations were observed when CIN3 was used as the endpoint. The findings from our study help to tag HPV31 variants that differ in risk of CIN2/3 and to explain in part why some HPV31 infections regress spontaneously and others lead to disease progression.
虽然已经认识到人类乳头瘤病毒 31 型(HPV31)变体的谱系,但它们的临床相关性尚不清楚。我们的研究目的是检查 HPV31 变体与宫颈上皮内瘤变 2-3 级(CIN2/3)的风险。研究对象为参加非典型鳞状细胞不明意义和低级别鳞状上皮内病变分流研究且在一次或多次就诊时检测到 HPV31 感染的女性。她们在 2 年内每半年随访一次,以检测 HPV DNA 和宫颈病变。通过 DNA 测序对 HPV31 分离株进行特征描述,并将其分为 3 个变体谱系之一。在 470 名 HPV31 阳性女性中,有 127 名(27.0%)组织学确诊为 CIN2/3,其中 83 名在首次 HPV31 阳性就诊时诊断出,44 名在随后的就诊中诊断出。与 C 变体相比,A 变体感染的 2 年累积 CIN2/3 风险比为 1.7(95%CI:1.0-2.9),B 变体感染的风险比为 2.2(95%CI:1.2-3.9)。在首次 HPV31 阳性就诊时没有 CIN2/3 的女性中,与 C 变体相比,A 变体感染的后续 CIN2/3 风险增加 2.2 倍(95%CI:1.0-4.8),B 变体感染的风险增加 2.0 倍(95%CI:0.9-4.9)。当 CIN3 作为终点时,观察到类似的关联。我们的研究结果有助于标记 HPV31 变体,这些变体在 CIN2/3 的风险上存在差异,并部分解释了为什么有些 HPV31 感染会自发消退,而有些则导致疾病进展。